68 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
program, supported by a robust data package and validated mechanism, including efficacy data from our Phase 2b X-TOLE clinical trial and read-outs from
8-K
EX-99.1
ld06b
8 Nov 22
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
424B5
rps 2496lo2ya2
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
bg1w 7w46uh8yyqozr
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
1tpke6
21 Jun 22
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
7:03am
424B5
j4piu5jyba2n3g4y
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
u3owo
6 Oct 21
Prospectus supplement for primary offering
5:05pm
424B5
i7eneubfx74d2c4
4 Oct 21
Prospectus supplement for primary offering
5:27pm